Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Study to Explore the Safety and Efficacy of ALS-L1023 in Patients With Non-alcoholic Steatohepatitis (NASH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALS L1023 (Primary)
Indications Non-alcoholic steatohepatitis
Focus Therapeutic Use
Sponsors AngioLab Inc

Most Recent Events

14 Nov 2023 Results assessing efficacy and safety of ALS-L1023 for the treatment of non-alcoholic fatty liver disease, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
09 Aug 2022 Status changed from recruiting to completed.
11 Jan 2021 Planned End Date changed from 4 Dec 2020 to 30 Sep 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com